Navigation Links
Aratana Therapeutics Drives Awareness of Pet Therapeutic Opportunity During "CVC Week" in Kansas City

KANSAS CITY, Kan., Sept. 3, 2013 /PRNewswire/ -- Aratana Therapeutics (Nasdaq: PETX), a development-stage biopharmaceutical company focused on the licensing, development and commercialization of innovative medications for pets (pet therapeutics), participated in several business development and leadership events during "CVC Week" in Kansas City.   The Conference for Veterinary Care (CVC) and adjunctive events, including the 2013 Animal Health Research Symposium and the Animal Health Early+Mid-Stage Investment Forum, were organized from August 23-27, 2013 to advance the growth and science of veterinary and animal care.

Showcasing its leadership position in the development and commercialization of innovative medications for pets, Aratana's Head of Drug Evaluation and Development, Ernst Heinen, DVM, Ph.D., delivered a presentation during the 2013 Animal Health Research Symposium entitled, "From Human Research To Pet Therapeutics."  Dr. Heinen's presentation highlighted the need for improved medications for dogs and cats, and the greenfield opportunity to develop drugs presently for human applications into therapeutics specifically for use in pets.

Separately, Aratana's Chief Scientific Officer, Linda Rhodes, VMD, Ph.D., a pioneer in the veterinary and animal health industry, presented the "2013 Innovation Award" at the Animal Health Early+Mid-Stage Investment Forum.   Sponsored by Aratana, the Innovation Award recognizes a single company that combines the most promising scientific and business opportunity. 

Steven St. Peter, M.D., President and Chief Executive Officer of Aratana Therapeutics, stated, "CVC Week is one of the significant annual events in animal health and veterinary care, and since we are a Kansas City-headquartered company, we are particularly pleased to play a leadership role in the emerging pet therapeutics space."

About Aratana Therapeutics
Aratana Therapeutics is a development-stage biopharmaceutical company focused on the licensing, development and commercialization of innovative medications for pets, or pet therapeutics. Aratana believes that it can leverage the investment in the human biopharmaceutical industry to bring therapeutics to pets in a capital and time efficient manner. Aratana's strategy is to in-license proprietary compounds from human biopharmaceutical companies and to develop these product candidates into therapeutics specifically for use in pets. Aratana believes the development and commercialization of these therapeutics will permit veterinarians and pet owners to manage pets' medical needs safely and effectively, resulting in longer and improved quality of life for pets.  For more information, please visit

Tiberend Strategic Advisors, Inc.

Joshua Drumm, Ph.D. (investors); (212) 375-2664

Andrew Mielach (media); (212) 375-2694

SOURCE Aratana Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Aratana to Participate in Leerink Swanns November Management Access Days
2. Aratana to Present at Bank of America Merrill Lynch Animal Health Summit
3. Aratana Therapeutics Appoints Erick Lucera Vice President of Corporate Development
4. Aratana Closes $12 Million Series C Financing to Fund Pipeline Expansion
5. Aratana Therapeutics to Present at Two Upcoming Healthcare Conferences
6. Aratana Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering
7. Aratana Therapeutics Reports Second Quarter 2013 Financial Results
8. Aratana Therapeutics to Host Pet Therapeutics Primer and Product Update Event
9. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
10. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
11. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
Post Your Comments:
(Date:6/23/2016)... LOS ANGELES , June 23, 2016 /PRNewswire/ ... (NASDAQ: CAPR ), a biotechnology company ... first-in-class therapeutics, today announced that patient enrollment in ... progrEssion in Duchenne) has exceeded 50% of its ... its enrollment in the third quarter of 2016, ...
(Date:6/23/2016)... Calif. , June 23, 2016 ... CST on Thursday, July 7, 2016 , , , , ... ) , , , , EXPERT PANELISTS:  , , ... Naik; Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar ... The global pharmaceutical industry is witnessing an exceptional ...
(Date:6/23/2016)... 23, 2016 Revolutionary technology includes ... Oticon , industry leaders in advanced audiology and hearing ... Oticon Opn ™, the world,s first internet connected hearing ... IoT devices.      (Photo: ... number of ,world firsts,: , TwinLink™ - ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their ... Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. , ... Pro X users can now reveal the media of their split screens with ...
(Date:6/26/2016)... ... , ... Quality metrics are proliferating in cancer care, and are derived from ... of the beholder, according to experts who offered insights and commentary in the current ... For the full issue, click here . , For the American Society of ...
(Date:6/26/2016)... Lake Orion, Clarkston, Michigan (PRWEB) , ... June ... ... direction with respect to fertility once they have been diagnosed with endometriosis. These ... tolerable intercourse but they also require a comprehensive approach that can help for ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room ... Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... A recent ... that most people are unfamiliar with. The article goes on to state that individuals ... also many of these less common operations such as calf and cheek reduction. The ...
Breaking Medicine News(10 mins):